Hexarelin

Evidence Limitation: The safety profile of hexarelin is based on limited clinical evidence. No dedicated clinical trials focusing on safety endpoints were identified, and most available data comes from preclinical studies and research on performance-enhancing peptide use.

Known Side Effects

Evidence on hexarelin's side effects in humans is extremely limited. The available literature primarily consists of preclinical studies examining protective effects in various disease models rather than systematic safety evaluations.

Evidence gap: No comprehensive human safety studies or clinical trials were identified that systematically document adverse effects, dosing limits, or safety parameters for hexarelin use.

Contraindications

Specific contraindications for hexarelin have not been established through clinical research. Given its mechanism as a growth hormone-releasing peptide that modulates the GH-IGF1 axis, theoretical contraindications may include conditions where growth hormone stimulation could be harmful, but this has not been clinically validated.

Drug Interactions

No documented drug interactions for hexarelin were identified in the available evidence. Research on peptide drug interactions with intestinal permeation enhancers and bile salts exists, but specific interaction profiles for hexarelin remain unstudied.

Populations That Should Avoid Use

Evidence gap: No clinical studies have identified specific populations that should avoid hexarelin use. Standard precautions for investigational compounds would suggest avoiding use in:

• Pregnant or breastfeeding women (no safety data available)
• Children and adolescents (no pediatric safety data)
• Individuals with hormone-sensitive conditions (theoretical concern due to GH-IGF1 axis effects)

Important Safety Considerations

The 2026 literature review on performance-enhancing peptides highlights a concerning "gap between clinical evidence and patient self-administration," indicating that hexarelin may be used outside of supervised research settings without adequate safety data.

Medical Disclaimer: Hexarelin is not approved for clinical use outside of research settings. This information is for educational purposes only and should not be considered medical advice. Consult with qualified healthcare professionals before considering any experimental treatments.

Bottom Line: The safety profile of hexarelin in humans remains largely unknown due to the absence of dedicated clinical safety studies. Any use should be restricted to supervised research settings until comprehensive safety data becomes available.